Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment

2019-09-12 02:34:41 | BioPortfolio


The purpose of this study is to investigate the effects of Dapagliflozin (FORXIGA) 10mg (n=20) versus placebo (n=20) administered orally, daily, in addition to current therapy, on the renal concentration mechanism, the mobilization skin and muscle Na+ stores, and the mobilization of muscle and liver fat stores in diabetic patients with heart failure New York Heart Association (NYHA) classes I and II, in a 4-week randomized, double-blind, placebo-controlled trial.


Sodium-glucose co-transporter-2 (SGLT-2) inhibitors improve cardiovascular outcomes with unprecedented reductions in cardiovascular mortality, renal disease progression, and heart failure hospitalizations, but the underlying mechanisms of these beneficial effects are unclear. The investigators hypothesize that the actions are not solely related to Na+ elimination and volume-related blood pressure reduction. Our previous work has shown that increased Na+ excretion leads to profound metabolic changes and energy utilization in the body in order to avoid water loss and dehydration. Our hypothesis is that dapagliflozin treatment induces high renal Na+ and glucose excretion predisposing to water loss, to which the body responds by concentrating the osmolytes into the urine, in an effort to prevent dehydration. Increased urea accumulation in the renal medulla, necessary to provide the osmotic driving force for water reabsorption, requires increased hepatic urea production, which is a costly, energy-intense process. This metabolic response leads to a reprioritization of energy metabolism in favour of amino-acid utilization in the liver, and a switch in fuel utilization in favour of fatty acids in the skeletal muscle.

Study Design


Diabetes Mellitus


Dapagliflozin 10 MG [Farxiga]


National Heart Centre Singapore




National Heart Centre Singapore

Results (where available)

View Results


Published on BioPortfolio: 2019-09-12T02:34:41-0400

Clinical Trials [4296 Associated Clinical Trials listed on BioPortfolio]

Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.

This is a Phase IV, single site, randomized, open-label, parallel study comparing BYDUREON-BCise plus FARXIGA to BYDUREON-BCise alone and FARXIGA alone in patients diagnosed with Type 2 Di...

Drug-drug Interaction Study of Dapagliflozin With Voglibose in Japanese Type 2 Diabetes Mellitus Patients

The purpose of this study is to evaluate the pharmacokinetics of dapagliflozin when administered alone or in combination with voglibose in Japanese patients with type 2 diabetes by assessm...

Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration

The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated group ...

Left Ventricular Functional Changes of Uncontrolled Diabetes by Dapagliflozin Treatment Trial

The primary purpose of this study is to evaluate the efficacy of the SGLT2 inhibitor dapagliflozin, as compared with standard care of diabetes, on left ventricular (LV) functional change i...

Dapagliflozin on Hyperlipidemia and Insulin Resistance in Type 2 Diabetic Patients (DAPHNIS Study)

The investigators will investigate whether dapagliflozin (FORXIGA) might improve lipoprotein metabolism as well as hyperglycemia in Japanese patients with type II diabetes mellitus whose H...

PubMed Articles [3832 Associated PubMed Articles listed on BioPortfolio]

Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.

To quantitatively compare pharmacokinetics (PK) and the exposure-response relationship of the sodium-glucose cotransporter-2 inhibitor, dapagliflozin, between adolescents/young adults and adults with ...

Use of Dapagliflozin in the Management of Type 2 Diabetes Mellitus: A Real-World Evidence Study in Indian Patients (FOREFRONT).

Dapagliflozin is approved in India based on a controlled clinical study. This study included type 2 diabetes mellitus (T2DM) Indian patients to determine effectiveness of dapagliflozin in the real-wor...

Glycaemic, weight, and blood pressure changes associated with early versus later treatment intensification with dapagliflozin in United Kingdom primary care patients with type 2 diabetes mellitus.

Early treatment intensification for type 2 diabetes mellitus (T2DM) is often required to achieve glycaemic control and avoid longer-term complications. We assessed associations between early versus la...

Efficacy and safety of Cinnamon in Type 2 Diabetes Mellitus and Pre-diabetes patients: A Meta-analysis and Meta-regression.

Cinnamon has been used as a dietary component and in the management of diabetes mellitus. This study systematically reviewed and synthesized evidence on the efficacy of cinnamon for the treatment of t...

Empagliflozin versus Dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week Prospective Observational Study.

To directly compare the effectiveness and safety between two distinct sodium-glucose co-transporter 2 (SGLT2) inhibitors, empagliflozin and dapagliflozin, as part of a quadruple oral antidiabetic agen...

Medical and Biotech [MESH] Definitions

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY.

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

A strain of Rattus norvegicus which is a model for spontaneous insulin-dependent diabetes mellitus (DIABETES MELLITUS, INSULIN-DEPENDENT).

More From BioPortfolio on "Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment"

Quick Search

Relevant Topics

Nephrology - kidney function
Nephrology is a specialty of medicine and pediatrics that concerns itself with the study of normal kidney function, kidney problems, the treatment of kidney problems and renal replacement therapy (dialysis and kidney transplantation). Systemic conditions...

Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...

Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...

Searches Linking to this Trial